Showing results (111-120 of 141) with videos related to
Sort By:
Pageof 15
Investigational New Drugs|February 15, 2014
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomachAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.Blood|January 18, 2011
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemiasJudith E Karp, B Douglas Smith, Linda S Resar, et al.Blood|January 17, 2004
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myelomaMelissa Alsina, Rafael Fonseca, Edward F Wilson, et al.Cancer Chemotherapy and Pharmacology|April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyTiciana B Leal, Scot C Remick, Chris H Takimoto, et al.Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.Cancer Immunology, Immunotherapy : CII|November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L Gulley, Philip M Arlen, Ravi A Madan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancerElaine T Lam, Matthew D Ringel, Richard T Kloos, et al.Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.Pageof 15